Licopid (Glucosaminylmuramyldipeptide) 1mg
Produced in Russia
Tablets 1 tab.
– 1 mg
– 10 mg
excipients: lactose; sucrose; potato starch; methylcellulose; calcium stearate
in a contour acheikova packing 10 pcs .; in a pack of cardboard 1 or 2 packages.
Complex therapy of conditions accompanied by secondary immunodeficiencies in adults and children.
Adults (tablets 1 and 10 mg):
chronic lung infections;
acute and chronic purulent-inflammatory diseases of the skin and soft tissues, including purulent-septic postoperative complications;
herpes infection (including ophthalmic herpes);
chronic viral hepatitis B and C;
psoriasis (including arthropathic form);
individual hypersensitivity to the drug;
autoimmune thyroiditis in the acute phase;
conditions in diseases accompanied by high fever or hyperthermia (> 38 ° C).
Method of administration and dosage:
Likopid is administered orally or sublingually on an empty stomach, 30 minutes before meals.
If you skip taking the drug, if no more than 12 hours have passed from the scheduled time, the patient can take the missed dose; if more than 12 hours have passed from the scheduled time of admission, it is necessary to take only the next dose according to the scheme and not to take the missed one.
Dose adjustment in certain groups of patients (elderly people, patients with impaired liver function, patients with impaired renal function) is not required.
Children; Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 1 tab. 1 time / day under the tongue for 10 days.
Chronic, recurrent infections of the upper and lower respiratory tract (in the stage of exacerbation and in the stage of remission): Likopid is taken in 3 courses of 1 tab. 1 time / day under the tongue for 10 days, with a break between courses of 20 days. Herpetic infection: 1 tab. 3 times / day by mouth or under the tongue for 10 days.
Adults; Chronic respiratory tract infections: 2 tab. 1 time / day under the tongue for 10 days. Acute and chronic purulent-inflammatory diseases of the skin and soft tissues (pyoderma, furunculosis and others): 2 tab. 2-3 times / day under the tongue for 10 days. Herpetic infection: 2 tab. 3 times / day by mouth or under the tongue for 10 days. To prevent or reduce the seasonal incidence of acute respiratory infections and the frequency of exacerbations of diseases of the ENT organs, upper and lower respiratory tract: 1 tab. 3 times / day under the tongue for 10 days.
The active substance of Licopid tablets is Glucosaminylmuramyldipeptide) (GMDP) – a synthetic analogue of the structural fragment of the membrane (peptidoglycan) of bacterial cells. GMDP is an activator of innate and acquired immunity, enhances the body’s defense against viral, bacterial and fungal infections; has an adjuvant effect in the development of immunological reactions.
The biological activity of the drug is realized through the binding of GMDP to the intracellular receptor protein NOD2, localized in the cytoplasm of phagocytes (neutrophils, macrophages, dendritic cells). The drug stimulates the functional (bactericidal, cytotoxic) activity of phagocytes, enhances the presentation of antigens by them, the proliferation of T and B lymphocytes, increases the synthesis of specific antibodies, and helps to normalize the balance of Th1 / Th2 lymphocytes towards the prevalence of Th1. The pharmacological action is carried out by increasing the production of key interleukins (interleukin-1, interleukin-6, interleukin-12), TNF alpha, gamma interferon, colony-stimulating factors. The drug increases the activity of natural killer cells.
Likopid has low toxicity (LD50 exceeds the therapeutic dose by 106,000 times or more). In the experiment with the oral route of administration in doses 100 times higher than the therapeutic one, the drug does not have a toxic effect on the central nervous system and the cardiovascular system, does not cause pathological changes in the internal organs.
Likopid does not have embryotoxic and teratogenic effects, does not cause chromosomal, gene mutations. In experimental studies carried out on animals, data on the antitumor activity of the drug Licopid (GMDP) were obtained.
In a dry, dark place at a temperature not exceeding 25 ° C.